Almaject Company Profile
What is the competitive landscape for ALMAJECT
ALMAJECT has seven approved drugs.
Summary for Almaject
| US Patents: | 0 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 7 |
| Patent Litigation for Almaject: | See patent lawsuits for Almaject |
Drugs and US Patents for Almaject
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almaject | CLINDAMYCIN PHOSPHATE | clindamycin phosphate | INJECTABLE;INJECTION | 062800-001 | Jul 24, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Almaject | TERIPARATIDE | teriparatide | SOLUTION;SUBCUTANEOUS | 218771-001 | Jun 4, 2024 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Almaject | DOXORUBICIN HYDROCHLORIDE | doxorubicin hydrochloride | INJECTABLE;INJECTION | 065515-001 | Nov 8, 2012 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Almaject | CLINDAMYCIN PHOSPHATE | clindamycin phosphate | INJECTABLE;INJECTION | 062943-001 | Sep 29, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Almaject | MELPHALAN HYDROCHLORIDE | melphalan hydrochloride | INJECTABLE;INJECTION | 204817-001 | May 17, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Almaject | CLINDAMYCIN PHOSPHATE | clindamycin phosphate | INJECTABLE;INJECTION | 062801-001 | Jul 24, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

